Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome

Nicholas L. Hartog, Eveline Y. Wu, Nicholas L. Rider, Yang Meng, Brian Hartline, Philippe Adams, Saurabh Aggarwal, Amanda Harrington

Open source

DOI
10.1007/s10238-025-01773-1
Published
2025-07-12
Container
Clinical and Experimental Medicine
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10238-025-01773-1,
  title = {Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome},
  author = {Nicholas L. Hartog and Eveline Y. Wu and Nicholas L. Rider and Yang Meng and Brian Hartline and Philippe Adams and Saurabh Aggarwal and Amanda Harrington},
  year = {2025},
  journal = {Clinical and Experimental Medicine},
  doi = {10.1007/s10238-025-01773-1},
  url = {https://doi.org/10.1007/s10238-025-01773-1}
}

RIS

TY  - JOUR
TI  - Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome
AU  - Nicholas L. Hartog
AU  - Eveline Y. Wu
AU  - Nicholas L. Rider
AU  - Yang Meng
AU  - Brian Hartline
AU  - Philippe Adams
AU  - Saurabh Aggarwal
AU  - Amanda Harrington
PY  - 2025
JO  - Clinical and Experimental Medicine
DO  - 10.1007/s10238-025-01773-1
UR  - https://doi.org/10.1007/s10238-025-01773-1
ER  - 

APA

Hartog, N. L., Wu, E. Y., Rider, N. L., Meng, Y., Hartline, B., Adams, P., Aggarwal, S., & Harrington, A. (2025). Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01773-1

Source records